Association of uric acid with mortality in patients with stable coronary artery disease

Related Experiment Videos

Gjin Ndrepepa1, Siegmund Braun, Lamin King

  • 1Deutsches Herzzentrum, Technische Universität, Munich, Germany. ndrepepa@dhm.mhn.de

Metabolism: Clinical and Experimental
|July 4, 2012
PubMed

Insights

High uric acid levels independently predict 1-year mortality in patients with stable coronary artery disease (CAD) undergoing percutaneous coronary intervention (PCI). This finding highlights uric acid as a significant prognostic marker in cardiovascular disease management.

Area of Science:

  • Cardiology
  • Clinical Biochemistry
  • Public Health

Background:

  • The relationship between uric acid and cardiovascular disease (CVD) requires further investigation.
  • Stable coronary artery disease (CAD) patients undergoing percutaneous coronary intervention (PCI) represent a key population for prognostic marker studies.

Purpose of the Study:

  • To determine if uric acid levels predict clinical outcomes in patients with stable CAD post-PCI.
  • To assess the independent predictive value of uric acid for 1-year mortality in this cohort.

Main Methods:

  • A cohort of 8149 patients with stable CAD who underwent PCI was analyzed.
  • Uric acid levels were measured before angiography; 1-year mortality was the primary endpoint.
  • Patients were stratified into quartiles based on uric acid levels, ranging from 1.49 to 21.90 mg/dl.

Main Results:

  • A significant association was observed between higher uric acid levels and increased 1-year mortality.
  • The highest quartile of uric acid showed a higher mortality rate (4.3%) compared to the lowest (1.8%).
  • Even after adjusting for cardiovascular risk factors, renal function, and inflammation, elevated uric acid remained an independent predictor of mortality (adjusted HR=1.26).

Conclusions:

  • Elevated uric acid levels are an independent predictor of 1-year mortality in patients with stable CAD treated with PCI.
  • Uric acid measurement can improve the predictive accuracy of existing mortality risk models in this patient group.
  • These findings suggest that monitoring uric acid may be valuable for risk stratification in stable CAD patients.
Abstract

Related Concept Videos

Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Coronary Artery Disease III: Clinical Manifestations01:30

Coronary Artery Disease III: Clinical Manifestations

Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...